Immunodeficiency Virus Patents (Class 424/148.1)
  • Publication number: 20150044137
    Abstract: Neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Inventors: John R. Mascola, Rebecca M. Lynch, Xueling Wu, Mark Connors, Tongqing Zhou, Joseph Casazza, Peter D. Kwong
  • Patent number: 8840890
    Abstract: The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: September 23, 2014
    Assignee: University of Maryland, Baltimore
    Inventors: George K. Lewis, Yongjun Guan
  • Patent number: 8828932
    Abstract: Disclosed herein are bifunctional molecules which inactivate human immunodeficiency virus (HIV) even before the virus attacks the target cell and inhibits HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV. Further disclosed are methods for prophylaxis against HIV and treatment of HIV infection.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: September 9, 2014
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Chungen Pan, Lu Lu
  • Publication number: 20140234332
    Abstract: The invention provides a novel strain of HIV-2 capable of causing immunodeficiency. The invention also provides compositions comprising the nucleic acids and polypeptides characteristic of this HIV-2 virus, antibodies specific for this HIV-2 virus, methods of using these compositions, and methods of detecting HIV-2 virus.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: Tulane University Health and Sciences Center
    Inventors: Stephen M. Smith, Preston A. Marx, JR.
  • Publication number: 20140205612
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 24, 2014
    Applicants: THERACLONE SCIENCES, INC., INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Patent number: 8747855
    Abstract: Provided are antibodies comprising an antigen recognition domain capable of binding an MHC molecule being complexed with a human immunodeficiency virus (HIV) peptide, wherein the antibody does not bind the MHC molecule in an absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC molecule. Also provided are methods of using same for diagnosing HIV infection and treating AIDS.
    Type: Grant
    Filed: April 5, 2009
    Date of Patent: June 10, 2014
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Yoram Reiter, Maya Haus-Cohen
  • Patent number: 8673307
    Abstract: Broad neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV, especially the preparation and use of highly neutralizing antibodies directed to HIV gp120 envelope protein, in the vaccination and treatment of HIV-infected patients.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: March 18, 2014
    Assignee: The Rockefeller University
    Inventors: Michel C. Nussenzweig, Johannes Scheid, John Pietzsch
  • Patent number: 8617553
    Abstract: Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: December 31, 2013
    Assignee: Aimsco Limited
    Inventors: Graham Joseph Peck, Juliette Peck
  • Patent number: 8535684
    Abstract: A method for identifying host genes and encoded proteins for potential targets for therapeutic intervention employs a Gene Search Vector that is either lentivirus or MMLV-based, and can be used to interrogate an entire cell genome without prior knowledge of the genomic sequence. This Random Homozygous Gene Perturbation (RUGP) technique is rapidly verifiable and is used to identify potential host targets for intervention for influenza, HIV and other viral infections. Using Thermal Assymetric Interlaced (TAIL)-PCR, the period for identification of promising targets is reduced from months to weeks or less. Specific targets including PTCH1, Robo1 and Nedd4 are reviewed in detail.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: September 17, 2013
    Assignee: Functional Genetics, Inc.
    Inventors: Michael S. Kinch, Michael Goldblatt, Wu-Bo Li, Douty Bamba, Shaojing Chang, Huosheng Chen, Zenbework Fesseha, Manu Kohli, Hanwen Mao, Heather Thi Thu Ung-Medoff, Ke Weng
  • Patent number: 8536137
    Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: September 17, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Bettina Beyreuther, Thomas Stöhr
  • Patent number: 8512702
    Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: August 20, 2013
    Assignee: Proscan Rx Pharma Inc.
    Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
  • Publication number: 20130195851
    Abstract: The present invention relates to articles of manufacture and methods for co-administration of antibodies and/or antibody-like molecules, and further concerns methods for intravenous administration of more than one antibody and/or antibody-like molecule to a subject in need from a stable mixture contained in the same article of manufacture, such as an intravenous infusion bag (IV bag).
    Type: Application
    Filed: December 21, 2012
    Publication date: August 1, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Publication number: 20130028908
    Abstract: Anti-HIV p17 monoclonal antibodies are described, which are capable of neutralizing the binding between multiple HIV-1 p17 protein variants and the p17R receptor are provided. Pharmaceutical compositions and methods of treatment utilizing these antibodies are also provided.
    Type: Application
    Filed: March 30, 2011
    Publication date: January 31, 2013
    Applicant: Medestea Research & Production S.p.A.
    Inventors: Arnaldo Caruso, Giulia Federica Merizzi, Antonio Soleti
  • Publication number: 20120294899
    Abstract: The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to HIV protein, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS.
    Type: Application
    Filed: July 15, 2011
    Publication date: November 22, 2012
    Inventors: Oleg IIiich Epshtein, Sergey Alexandrovich Tarasov
  • Patent number: 8246957
    Abstract: Disclosed are monoclonal antibodies and antibody fragments which recognize antigens encoded by HERV DNA sequences, and methods for production, including recombinant antibody fragments derived from lymphoid cells of lupus patients that make antibodies which neutralize HIV.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: August 21, 2012
    Inventor: Sudhir Paul
  • Publication number: 20120183557
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan BARNETT, Rino RAPPUOLI, Victoria A. SHARMA, Indresh K. SRIVASTAVA, Jan ZUR MEGEDE
  • Publication number: 20120177657
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 12, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Vega MASIGNANI, Maria SCARSELLI, Barbara CAPECCHI, Victoria SHARMA, Susan W. BARNETT, Indresh K. SRIVASTAVA, Rino RAPPUOLI
  • Publication number: 20120039984
    Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.
    Type: Application
    Filed: July 2, 2009
    Publication date: February 16, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Geert-Jan Boons, Therese Buskas, Alex J. Harvey, Sampat Ingale, Margaretha Wolfert, Robert Lance Wells
  • Patent number: 8110192
    Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: February 7, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Mei-Yun Zhang
  • Publication number: 20110236393
    Abstract: The presently disclosed subject matter provides methods of inhibiting a host innate response to activator-mediated proliferative signals in a primary B cell. In some embodiments a method is provided for immortalized primary B cells. In some embodiments a method is provided for increasing efficiency of EBV transformation of primary B cells. In some embodiments a method is provided for increasing proliferation of primary B cells in culture. In some embodiments a method is provided for producing a monoclonal antibody. In some embodiments a method is provided for identifying a novel broadly neutralizing antibody having a desired antigen specificity. Also provided are antibodies produced according the methods of the presently disclosed subject matter.
    Type: Application
    Filed: November 4, 2009
    Publication date: September 29, 2011
    Inventors: Kwan-ki Hwang, Micah Luftig
  • Patent number: 7993647
    Abstract: The present invention provides monoclonal antibodies to HIV-1 Vpr and hybridoma cell lines that produce the monoclonal antibodies to HIV-1 Vpr. Methods for use of such antibodies in the detection of HIV-1 infection are also provided.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: August 9, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey B. Kopp, Terence M. Phillips, Ulrich Schubert, John Yewdell
  • Publication number: 20110177090
    Abstract: The present invention provides compositions and methods for the specific and sensitive detection and characterization of anti-carbohydrate antibodies against immunogenic sugar moieties on microbes and abnormal cells and anti-HIV-1 protein antibodies for the development of diagnostic, prophylactic and therapeutic strategies against diseases inflicted by cancer cells or microbial pathogens.
    Type: Application
    Filed: January 19, 2011
    Publication date: July 21, 2011
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Denong Wang, Leonore A. Herzenberg
  • Publication number: 20110142847
    Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 16, 2011
    Applicants: Panacos Pharmaceuticals, Inc., GOVERNMENT OF THE U.S., REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Carl T. Wild, Carol D. Weiss
  • Patent number: 7897332
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: March 1, 2011
    Assignee: Abbott Laboratories
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Publication number: 20110044994
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Application
    Filed: March 17, 2010
    Publication date: February 24, 2011
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Publication number: 20110044995
    Abstract: The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies: (a) an antibody having the amino acid sequence shown in SEQ ID NO: 1 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 2 as the amino acid sequence of a L chain variable region (VL); and (b) an antibody having the amino acid sequence shown in SEQ ID NO: 3 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 4 as the amino acid sequence of a L chain variable region (VL).
    Type: Application
    Filed: November 19, 2008
    Publication date: February 24, 2011
    Applicant: KUMAMOTO UNIVERSITY
    Inventors: Shuzo Matsushita, Kazuhisa Youshimura
  • Publication number: 20110033446
    Abstract: The present invention provides novel methods for treating and preventing coronary artery disease in HIV-1-infected individuals by interfering with Nef-mediated effect on ABCA1. The invention further provides novel methods for suppressing HIV infection by stimulating cholesterol efflux from cells by stimulating expression of ABCA1 in HIV-1-infected individuals. These methods take advantage of the finding that Nef, a regulatory protein of HIV-1, (1) diminishes expression of ATP-binding cassette transporter A1 (ABCA1), the main transporter of cholesterol from cells to extracellular acceptors; and (2) impairs cholesterol efflux from HIV-1-infected macrophages leading to cholesterol accumulation and formation of foam cells, which is a characteristic feature of atherosclerosis.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 10, 2011
    Inventors: Michael Bukrinsky, Dmitri Sviridov
  • Patent number: 7858298
    Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells effective to prevent fusion of HIV-1 to CD4+ cells and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: December 28, 2010
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon, William C. Olson
  • Publication number: 20100183622
    Abstract: Pharmaceutical compositions comprising the HIV protein vpr or nucleic acid molecule encoding vpr are disclosed. Also disclosed are methods of treating patients suffering from diseases characterized by hyperproliferating undifferentiated cells such as cancer by administering such compositions. Methods of identifying compounds which have anti-HIV activity are disclosed, in particular, methods of identifying compounds which modulate the activity of vpr and of identifying compounds which inhibit vpr binding to the HIV protein gag.
    Type: Application
    Filed: January 9, 2008
    Publication date: July 22, 2010
    Inventors: David B. Weiner, David Nathan Levy, Yosef Refaeli
  • Patent number: 7744887
    Abstract: Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed which encode relevant portions of these antibodies, as well as the purified forms of the expressed antibodies or relevant antibody fragments, such as VH and VL chains. The antibody compositions disclosed within this specification may provide for a therapeutic treatment against HIV infection by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV infection. These antibodies will also be useful in assays to identify HIV antiviral compounds as well as allowing for the identification of candidate HIV vaccines, such as HIV peptide vaccines.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: June 29, 2010
    Assignees: Merck & Co., Inc., Whitehead Insitute of Biomedical Research, MedImmune Limited, Istitute di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: John W. Shiver, Michael D. Miller, Romas Geleziunas, Daria J. Hazuda, Peter S. Kim, Debra M. Eckert, Michael J. Root, Simon N. Lennard, Elisabetta Bianchi
  • Publication number: 20100124553
    Abstract: Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ cells into HIV-infected patients.
    Type: Application
    Filed: June 17, 2009
    Publication date: May 20, 2010
    Inventor: Johnson T. Wong
  • Publication number: 20100040631
    Abstract: Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors with different target sites in HIV gp41 or different mechanisms of action. Also disclosed are methods of treating HIV infection by administering such compositions.
    Type: Application
    Filed: August 12, 2009
    Publication date: February 18, 2010
    Inventors: Shibo Jiang, Chungen Pan
  • Patent number: 7595050
    Abstract: A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting with HIV-infected cells, inducing apoptosis in the infected cells and thus disrupting the cells, etc.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: September 29, 2009
    Assignee: Nagoya Industrial Science Research Institute
    Inventors: Hidechika Okada, Noriko Okada
  • Patent number: 7595049
    Abstract: The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E10-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: September 29, 2009
    Assignee: Polymun Scientific Immunobiologische Forschung GmbH
    Inventors: Gabriela Stiegler, Renate Kunert, Hermann Katinger
  • Patent number: 7582302
    Abstract: The invention provides a novel method of vaccination of an animal of the felidae family against feline leukemia. The FeLV recombinant vaccine based on viral vector with the aid of a liquid jet needle-free injector can result in distribution of the vaccine essentially in the dermis and the hypodermis of the animal.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: September 1, 2009
    Assignee: Merial Limited
    Inventors: Tesfai Tseggai, Maria Camila Pardo, Alton Timothy Leard
  • Publication number: 20090191216
    Abstract: The invention relates to a monoclonal antibody or a fragment thereof, recognizing a peptide of sequence set forth as SEQ ID NO 7 or an analogue thereof, wherein the complementarity determining region 3 (CDR3) of its H chain variable region comprises the peptide sequence set forth as SEQ ID NO 1 or a functional analogue thereof.
    Type: Application
    Filed: November 1, 2007
    Publication date: July 30, 2009
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Morgane Bomsel, Daniela Tudor
  • Patent number: 7566451
    Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: July 28, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Mei-Yun Zhang
  • Publication number: 20080138351
    Abstract: One can treat a viral infection such as hepatitis B (HBV), hepatitis C (HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N-butyl deoxynojirimycin (NB-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of NB-DNJ directly into the ER can be also applied for the treatment of other viruses, for which NB-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV).
    Type: Application
    Filed: August 2, 2007
    Publication date: June 12, 2008
    Inventors: Raymond A. Dwek, Norica Nichita-Branza, Stefana Petrescu, Stephanie Pollock, Pauline Rudd, Christopher Scanlan, Nicole Zitzmann
  • Patent number: 7306798
    Abstract: The invention relates to a novel variant of isolated and/or purified immunoglobulin IgG3 which can be used as a marker for protecting against infectious viral diseases such as AIDS, as a diagnostic tool, or as a preventive and curative medicament. The invention also relates to corresponding in vitro diagnostic methods.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: December 11, 2007
    Assignees: Urrma R & D, Urrma Biopharma
    Inventors: Jean-Claude Chermann, Camille Haslin, Ricardo De Oliveira
  • Patent number: 7226429
    Abstract: The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Accordingly, the present invention provides a method for reducing viral load in an individual comprising the steps of obtaining blood or plasma from the individual, passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are immobilized within the porous exterior portion of the membrane, collecting pass-through blood or plasma and reinfusing the pass-through blood or plasma into the individual.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: June 5, 2007
    Assignee: Aethlon Medical, Inc.
    Inventor: Richard H. Tullis
  • Patent number: 7223844
    Abstract: The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: May 29, 2007
    Assignees: United States of America, Represented by the Secretary, Department of Health and Human Services, Scripps Research Institute
    Inventors: Dimiter S. Dimitrov, Maxime Moulard, Xiadong Xiao, Yuuei Shu, Sanjay K. Phogat, Mei-Yun Zhang, Dennis Burton
  • Patent number: 7122188
    Abstract: This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1, mixtures of antibodies which bind with immune complexes comprising the HIV-1 proteins, immune complexes comprising p12 or p18 proteins of HIV-1, and methods for production of antibodies against p2 or p18 proteins of HIV-1.
    Type: Grant
    Filed: May 26, 1993
    Date of Patent: October 17, 2006
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Bruil, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
  • Patent number: 7060273
    Abstract: This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: June 13, 2006
    Assignee: Progenics Pharmaceuticals, Inc.
    Inventors: William C. Olson, Paul J. Maddon
  • Patent number: 7045130
    Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: May 16, 2006
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Marc Alizon, Pierre Sonigo, Cole Stewart, Oliver Danos, Simon Wain-Hobson
  • Patent number: 7041293
    Abstract: The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: May 9, 2006
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Florian M. Wurm
  • Patent number: 7008622
    Abstract: A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compositions can contain the antibodies induced by the peptide compositions for use in passive therapy. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: March 7, 2006
    Assignee: Thymon, L.L.C.
    Inventor: Gideon Goldstein
  • Publication number: 20040241641
    Abstract: The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E1O-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12.4E1O-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E1O-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies.
    Type: Application
    Filed: March 18, 2004
    Publication date: December 2, 2004
    Inventors: Gabriela M Stiegler, Renate Kunert, Hermann Katinger
  • Patent number: 6803449
    Abstract: A monoclonal antibody specific to Nap was prepared by using a crude membrane fraction from a cell line which has a high affinity to Nef as an antigen. A cDNA clone which encodes Nap was obtained by screening a cDNA library of said cell line utilizing the specific antibody. The nucleotide sequence of this cDNA was elucidated whereupon the full amino acid sequences of human Nap was identified. Since the anti-Nap monoclonal antibody inhibits the binding of Nef to Nap, it can be used as a new therapeutic agent for AIDS. In addition, it can be applied for the diagnosis of AIDS by clarifying the relation between the expression of Nap and the development of AIDS. Nap can be utilized for binding experiments to Nef.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: October 12, 2004
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Yoichi Fujii, Kaori Otake
  • Publication number: 20040141998
    Abstract: Disclosed are methods of stimulating in a subject an immune response to an antigen to which the immune response is targeted. This method includes the step of administering to the subject a binding agent which binds a surface receptor of an antigen-presenting cell, in some instances without being blocked substantially by the natural ligand for the surface receptor, and an antigen to which the immune response is targeted, in a physiologically acceptable medium to the subject. Also disclosed are molecular complexes including the binding agent coupled to an antigen.
    Type: Application
    Filed: July 15, 2003
    Publication date: July 22, 2004
    Inventors: Jean Loup Romet-Lemonne, Michael W. Fanger, Paul M. Guyre, Edmund J. Gosselin
  • Publication number: 20040109861
    Abstract: Isolated protein complexes are provided comprising Tsg101 and HIV GAG or GAGp6. The protein complexes are useful in screening assays for selecting compounds effective in modulating the Tsg101-HIV GAG or GAGp6 interaction within the protein complexes.
    Type: Application
    Filed: September 15, 2003
    Publication date: June 10, 2004
    Applicant: Myriad Genetics, Incorporated
    Inventors: Kenton Zavitz, Scott Morham, Daniel Albert Wettstein